D. Kaloudas

Targeting bacterial TPP riboswitches using pVEC-conjugated chimeric antisense oligonucleotides.

Design and applications of chimeric antisense oligonucleotides that bind TPP mRNAs as antibacterial agents.

The rapid emergence of antibiotic-resistant bacteria has created an urgent need for innovative therapeutic strategies that go beyond conventional small-molecule antibiotics. Among the most promising approaches is the use of nucleic acid-based therapeutics, particularly antisense oligonucleotides (ASOs), which offer hig...

Molecular phylogenetics, distribution and evolution of the TPP riboswitch

Pharmacogenetics and Pharmacogenomics as Enabling Technologies for Precision Drug Development and Personalized Therapy.

How pharmacogenetics and pharmacogenomics function as enabling technologies across the pharmaceutical and clinical domains is synthesized, with emphasis on biomarker-guided drug development, patient stratification, safety optimization, regulatory translation, precision oncology, sex-related variability, population dive...